These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33268818)

  • 1. Correlation of anti-tumour drug resistance with epigenetic regulation.
    Hayashi T; Konishi I
    Br J Cancer; 2021 Feb; 124(4):681-682. PubMed ID: 33268818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tackling drug resistance in ovarian cancer with epigenetic targeted drugs.
    Zhao L; Guo H; Chen X; Zhang W; He Q; Ding L; Yang B
    Eur J Pharmacol; 2022 Jul; 927():175071. PubMed ID: 35636522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer.
    Borley J; Brown R
    Ann Med; 2015; 47(5):359-69. PubMed ID: 26158617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
    Gyparaki MT; Papavassiliou AG
    Clin Breast Cancer; 2018 Jun; 18(3):189-191. PubMed ID: 29042129
    [No Abstract]   [Full Text] [Related]  

  • 5. Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic Regulators.
    Rauscher S; Greil R; Geisberger R
    Curr Cancer Drug Targets; 2021; 21(4):353-359. PubMed ID: 33423645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities.
    Shah K; Rawal RM
    Curr Drug Metab; 2019; 20(14):1114-1131. PubMed ID: 31902353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.
    Chapman-Rothe N; Curry E; Zeller C; Liber D; Stronach E; Gabra H; Ghaem-Maghami S; Brown R
    Oncogene; 2013 Sep; 32(38):4586-92. PubMed ID: 23128397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
    Calcagno AM; Fostel JM; To KK; Salcido CD; Martin SE; Chewning KJ; Wu CP; Varticovski L; Bates SE; Caplen NJ; Ambudkar SV
    Br J Cancer; 2008 May; 98(9):1515-24. PubMed ID: 18382425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using Epigenetic Therapy to Overcome Chemotherapy Resistance.
    Strauss J; Figg WD
    Anticancer Res; 2016 Jan; 36(1):1-4. PubMed ID: 26722021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer's epigenetic drugs: where are they in the cancer medicines?
    Ghasemi S
    Pharmacogenomics J; 2020 Jun; 20(3):367-379. PubMed ID: 31819161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance.
    Wilting RH; Dannenberg JH
    Drug Resist Updat; 2012; 15(1-2):21-38. PubMed ID: 22356866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular targets for epigenetic therapy of cancer.
    Humeniuk R; Mishra PJ; Bertino JR; Banerjee D
    Curr Pharm Biotechnol; 2009 Feb; 10(2):161-5. PubMed ID: 19199948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer.
    Matei DE; Nephew KP
    Gynecol Oncol; 2010 Feb; 116(2):195-201. PubMed ID: 19854495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
    Bai H; Cao D; Yang J; Li M; Zhang Z; Shen K
    J Cell Mol Med; 2016 Apr; 20(4):581-93. PubMed ID: 26800494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
    Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poised epigenetic states and acquired drug resistance in cancer.
    Brown R; Curry E; Magnani L; Wilhelm-Benartzi CS; Borley J
    Nat Rev Cancer; 2014 Nov; 14(11):747-53. PubMed ID: 25253389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.
    Chen S; Zhao Y; Liu S; Zhang J; Assaraf YG; Cui W; Wang L
    Drug Resist Updat; 2022 Mar; 61():100821. PubMed ID: 35219075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
    Perez-Plasencia C; Duenas-Gonzalez A
    Mol Cancer; 2006 Jul; 5():27. PubMed ID: 16831224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
    Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.